Scientific deep-dive

Semaglutide and Muscle Mass: What the STEP Trial Sub-Analyses Actually Show

Lean body mass loss is the most underreported side effect of GLP-1 weight loss. We summarize the STEP-1 DEXA sub-analysis and what it means for older adults and resistance-trained patients.

By Eli Marsden · Founding Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
14 min read·15 citations

Every weight-loss intervention — surgical, pharmaceutical, or dietary — takes some of the weight from lean tissue rather than fat. The interesting question is how much. For semaglutide, the answer matters because the drug is increasingly prescribed to populations where preserving muscle is medically important: older adults, post-menopausal women, and people with type 2 diabetes who already have lower baseline lean mass.

The headline number that has been circulating in popular coverage — that 20–40% of weight lost on a GLP-1 receptor agonist is lean body mass — is in the right range, but it deserves unpacking. A 2024 review found that reported shares vary widely, from 40–60% of weight lost in some studies to about 15% or less in others, and the best-measured trial data below cluster near 25%.[15] The picture is more nuanced than either the “semaglutide melts your muscles” takes or the defensive industry response that “all weight loss looks like this” would suggest. Both can be true at the same time.

Compare vetted compounded semaglutide providers

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money

No insurance needed · HSA/FSA eligible · vetted by our editors

8.3

Collective

The lowest flat medication price if you can absorb an annual membership fee

Starting price: $59/mo (+ required membership)

Get started →Read review Collective →
8.3

CoreAge Rx

Lowest-price compounded semaglutide and tirzepatide with one flat price at every dose

Starting price: $79/mo (“starting at” price)

Get started →Read review CoreAge Rx →
7.8

Embody

Low flat-rate compounded GLP-1 pricing at every dose

Starting price: $79/mo (sale price)

Get started →Read review Embody →
8.2

Gala

Compounded semaglutide or tirzepatide at one all-doses price on a yearly plan, with free shipping

Starting price: $129/mo (starting dose)

Get started →Read review Gala →
8.3

Found

Medication-included compounded GLP-1 from $169/mo on a 12-month prepaid plan, plus brand insurance help

Starting price: $169/mo (12-month plan rate)

Get started →Read review Found →

What the trials actually measured

STEP 1 was the pivotal phase 3 trial that put semaglutide on the weight-loss map. 1,961 adults with overweight or obesity (and without type 2 diabetes) were randomized 2:1 to weekly subcutaneous semaglutide 2.4 mg or placebo, both layered on top of lifestyle intervention. After 68 weeks, the semaglutide arm had lost a mean of 14.9% of body weight, versus 2.4% in the placebo arm.[1]

The body-composition picture for GLP-1 receptor agonists comes from several sources. The most directly comparable is the SURMOUNT-1 body-composition sub-study (Look et al., Diabetes Obes Metab 2025), which used DEXA in 160 participants from the tirzepatide pivotal obesity trial. At week 72, the tirzepatide arm lost 21.3% of body weight, with fat mass falling 33.9% and lean mass falling 10.9%. Roughly 75% of the weight lost was fat mass and 25% was lean mass — and the same ~75/25 split was seen in the placebo arm, suggesting the proportional composition of the loss was no different than diet alone.[2]

A 2025 systematic review and network meta-analysis by Karakasis and colleagues pooled 22 randomized trials of GLP-1 receptor agonists and co-agonists (2,258 participants) and found that across the class, lean mass accounts for approximately 25% of total weight loss. Semaglutide and tirzepatide produced the largest absolute fat loss but were among the least effective at preserving lean mass relative to other agents.[3]

The qualifier that matters: the proportion of lost weight that comes from lean tissue during GLP-1 therapy is comparable to what you see in unstructured caloric restriction of similar magnitude. The Heymsfield 2024 modeling paper in Obesity, built from MRI scans of 897 healthy nonexercising adults and checked against two longitudinal weight-loss studies, estimated that men lose roughly 26% of weight as skeletal muscle during voluntary calorie restriction without exercise, and women roughly 14%. Skeletal muscle is only part of lean mass, so these figures run lower than lean-mass shares. In other words, GLP-1s aren't uniquely catabolic — fast weight loss without resistance training and adequate protein causes lean-mass loss across the board, and GLP-1s simply make fast weight loss possible at scale for the first time.[4]

How that compares to other weight-loss methods

For context, here's what the literature shows for the share of lost weight that comes from lean mass across several well-studied interventions:

  • Bariatric surgery (Roux-en-Y). In a DXA study of 42 women, lean mass made up 9.8 kg of the 36.0 kg lost at one year, about 27%. Lean-mass loss leveled off after 3 to 6 months while fat mass kept falling.[6]
  • Caloric restriction (general). Modeling across pooled cohorts puts the share at roughly 26% of weight loss as skeletal muscle in men and 14% in women without structured exercise.[4]
  • Very low calorie diets and intermittent fasting. Lean-mass loss varies widely and depends heavily on protein intake and concurrent resistance training. In one 8-week trial in resistance-trained women eating 1.6 g/kg/day of protein, time-restricted eating did not blunt fat-free mass gains.[7][8]
  • Tirzepatide (SURMOUNT-1 sub-study). ~25% lean-mass share over 72 weeks — the same proportional split as the placebo arm of the same trial.[2][9]

The takeaway: semaglutide isn't catastrophically worse than other major interventions on lean-mass preservation, but it also isn't magically better. The percentages are similar; the difference is that semaglutide produces dramatically more total weight loss in routine clinical use, which means the absolute number of pounds of lean mass lost is larger even when the percentage is normal.

Magnitude comparison

Share of total weight loss attributable to lean mass across major weight-loss interventions. SURMOUNT-1 DXA sub-study tirzepatide arm and the placebo arm of the same trial showed the same ~25% proportional split; Karakasis 2025 network meta-analysis put the class average at about 25%. The Heymsfield 2024 calorie-restriction figures are skeletal muscle only (14% in women, 26% in men), a subset of lean mass.[2][3][4][6]

  • Caloric restriction without exercise — women (Heymsfield 2024)14 % of weight lost as skeletal muscle
  • Tirzepatide (pooled 5, 10 and 15 mg) — SURMOUNT-1 DXA sub-study, 72 wk25 % of weight lost as lean mass
    10.9% lean mass decline on 21.3% TBWL; same ~75/25 split as the placebo arm
  • Placebo arm — SURMOUNT-1 DXA sub-study25 % of weight lost as lean mass
    diet-driven loss alone — proportionally identical to the drug arm
  • GLP-1 / co-agonist class average — Karakasis 2025 NMA (22 RCTs)25 % of weight lost as lean mass
  • Caloric restriction without exercise — men (Heymsfield 2024)26 % of weight lost as skeletal muscle
  • Bariatric surgery (Roux-en-Y) — Ciangura 201027 % of weight lost as lean mass
    9.8 kg lean of 36.0 kg lost at 1 year, 42 women
Share of total weight loss attributable to lean mass across major weight-loss interventions. SURMOUNT-1 DXA sub-study tirzepatide arm and the placebo arm of the same trial showed the same ~25% proportional split; Karakasis 2025 network meta-analysis put the class average at about 25%. The Heymsfield 2024 calorie-restriction figures are skeletal muscle only (14% in women, 26% in men), a subset of lean mass.

Why this matters more for some patients than others

Not every kilogram of lean mass loss is equal. Lean body mass is an aggregate that includes skeletal muscle, organ tissue, bone mineral, and intracellular water. When weight drops fast, intracellular water shifts can account for a meaningful chunk of early “lean” loss without representing actual muscle atrophy. That's the strongest argument for not panicking about the headline number, and it is the central point of a 2024 JAMA viewpoint by Conte, Hall and Klein arguing that the clinical relevance of GLP-1-induced fat-free mass loss in most adults with obesity has been overstated.[7][5]

But the patients where the concern is real and not theoretical are:

  • Adults over 65. Sarcopenia — age-related muscle loss — builds with age. An older patient losing 6 kg of lean mass on top of natural sarcopenia can plausibly cross the threshold into functional impairment (slower gait speed, reduced grip strength, higher fall risk).[10]
  • Post-menopausal women. The estrogen drop at menopause already accelerates muscle and bone loss. Layered on top of GLP-1 weight loss without a resistance program, this population shows the largest decrements in DEXA lean mass.
  • Patients with sarcopenic obesity at baseline. A subset of obese patients already have low muscle mass relative to their body size before starting any weight-loss program. They're the highest-risk group, and ironically the group most likely to benefit from the metabolic effects of weight loss. Resistance training matters most for them.[11]
  • People with type 2 diabetes. Diabetes itself accelerates muscle loss through insulin resistance and chronic inflammation. The combined effect of diabetes plus rapid weight loss can be larger than either alone.

What the trials show actually preserves lean mass

The good news is that exercise alongside GLP-1 therapy has been studied directly, and the results are encouraging. In a trial by Sandsdal and colleagues (Cardiovascular Diabetology, 2023), 195 adults with obesity first lost 12% of body weight on an 8-week low-calorie diet and were then randomized for one year. Compared with placebo, abdominal fat percentage fell 6.1 percentage points with exercise plus liraglutide 3.0 mg, versus 2.8 with liraglutide alone and 2.6 with exercise alone. That trial measured abdominal fat and metabolic syndrome severity, not lean mass directly.[12]

The interventions that have actually been tested in trials and show meaningful effect:

  1. Resistance training, 2–3 sessions per week, progressive overload. Doesn't need to be a gym program — bodyweight protocols and resistance bands have been shown to work in older adults. The dose-response relationship favors heavier loads when tolerable. Volume matters more than session length.
  2. Protein intake of 1.2–1.6 g/kg body weight per day. Higher than the standard 0.8 g/kg RDA. For a 75 kg person, that's roughly 90–120 g per day. Spread across meals because GLP-1s slow gastric emptying and you can run into satiety problems trying to hit the target in one sitting.[13]
  3. Maintaining intake even during early appetite suppression. The early months on semaglutide, while the dose climbs, are when appetite changes are most noticeable. Letting calorie and protein intake fall very low during this window works against lean-mass preservation. Forcing protein intake even when not hungry is the single most actionable lever.
  4. Vitamin D and creatine. Smaller effects, both well-tolerated. For creatine, a meta-analysis of 357 older adults found that adding it to resistance training increased fat-free mass gains over training alone.[14]

Notice what isn't on the list: branched-chain amino acid supplements, “anabolic” nutraceuticals, leucine powders, or any of the marketing categories sold around GLP-1s. None of these have trial-grade evidence for preserving lean mass during pharmaceutical weight loss.

The clinical bottom line

The fair summary of the evidence: semaglutide produces lean-mass loss in roughly the same proportion as other rapid weight-loss methods, but the absolute amount is larger because the absolute weight loss is larger. For most patients under 60 with normal baseline muscle mass and any kind of physical activity, the clinical significance of the lean-mass loss is small relative to the cardiovascular, metabolic, and quality-of-life benefits of the weight loss itself.

For older patients, post-menopausal women, and anyone with sarcopenic obesity, the picture changes — and the evidence-based response is not to avoid GLP-1s but to layer resistance training and protein intake on top of them. That combination has been studied, and it works.

The thing worth keeping in view: in the SURMOUNT-1 body-composition sub-study, fat mass fell about three times faster than lean mass on tirzepatide, and the proportional ~75/25 split of weight loss into fat versus lean was no different from the placebo arm of the same trial. That's the finding consistent with the cardiovascular and metabolic outcome benefits seen in SELECT and other post-marketing trials of GLP-1 receptor agonists. From a longevity and metabolic-health standpoint, the trade is heavily favorable for almost every patient who would clinically qualify for the drug.[2]

If you're weighing semaglutide and the muscle-loss concern is what's holding you back, the right question isn't “is this drug catabolic?” It's “am I willing to lift weights twice a week and eat enough protein while I'm on it?” If the answer is yes, the data suggests you'll come out the other side leaner, healthier, and not meaningfully weaker. If the answer is no, the trade is less obviously favorable — and that's a conversation worth having with the prescribing clinician before starting. If you decide to move forward, our ranked semaglutide providers compare the vetted telehealth options.

Related research

For the broader picture beyond body composition:

  • What happens when you stop taking semaglutide — STEP-4, STEP-1 extension, and SURMOUNT-4 on weight regain after discontinuation. Lean mass loss during treatment is one half of the body composition story; weight regain after stopping is the other.
  • GLP-1 side effects from the RCT adverse-event tables — including the “Ozempic face” discussion and how it relates to the lean-mass loss documented above.
  • What SELECT showed about cardiovascular outcomes — semaglutide's 20% MACE reduction in non-diabetic adults with established CVD, and the finding that the cardiovascular benefit appears largely independent of how much weight patients actually lost.
  • Exercise pairing for lean-mass preservation — the resistance-training protocols that the published literature shows mitigate the lean-mass loss documented above.
  • What is tai chi walking for weight loss? — companion low-intensity mind-body modality. Tai chi is NOT a primary lean-mass-preservation lever (resistance training has stronger myofibrillar stimulus) but is the strongest evidence-based fall-prevention exercise in the PubMed literature (Sherrington 2019 Cochrane PMID 30703272, high-certainty −20% people-falling endpoint). Particularly relevant for older patients losing weight rapidly on GLP-1 therapy, where transient balance impairment during lean-tissue loss increases fall risk.
  • GLP-1 protein calculator — calculates your daily protein target with the GLP-1 bump applied, anchored on the Neeland 2024 lean-mass mitigation review.
  • How to calculate macros for weight loss — the four-step Mifflin-St Jeor BMR + FAO/WHO TDEE + Hall 2011 deficit + Morton 2018 protein-floor walkthrough that underwrites the calculator above, with a higher GLP-1 protein target and the Mamerow 2014 per-meal distribution rule.
  • Best protein powder for weight loss: evidence review — third-party certification criteria (NSF Certified for Sport, USP Verified, Informed Sport), whey vs casein vs plant evidence from the Lim 2021 meta-analysis (PMID 33670701), per-meal dosing per the ISSN 2017 position stand, and protein timing for GLP-1 users aiming for a higher protein target.
  • Is cottage cheese good for weight loss? — the whole-food casein vehicle for pre-sleep protein delivery, the strongest mitigation lever against the overnight catabolic window that compounds GLP-1 lean-mass loss. Covers Res 2012 (40 g pre-sleep casein increased overnight MPS by ~22%, PMID 22330017), Snijders 2015 (12-wk pre-sleep casein RCT + resistance training, PMID 25926415), and the Leyh/Ormsbee 2018 cottage-cheese-vs- casein-powder equivalence trial (PMID 30249314).
  • Are protein shakes good for weight loss? — the powdered + RTD + meal-replacement category that most GLP-1 patients use as the practical bridge to the higher daily protein target when whole-food intake collapses under appetite suppression. Covers the Heymsfield 2003 meal-replacement meta-analysis (PMID 12704397), Astbury 2019 meal-replacement systematic review (PMID 30675990), Wycherley 2012 high-protein- hypocaloric meta-analysis (PMID 23097268), and the Mathai 2017 DIAAS source-quality framework (PMID 28382889).
  • Loose skin after GLP-1 weight loss — the downstream consequence of inadequate lean-mass preservation during rapid weight loss.
  • How to tighten skin after weight loss naturally — the consumer-action companion: protein and resistance training framework, sustainable rate of loss, smoking cessation and daily SPF, the Ngaage 2020 panniculectomy insurance-coverage criteria, and the risk-score framework for estimating redundancy magnitude.

Further reading

References

  1. 1.Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021. PMID: 33567185.
  2. 2.Look M, Dunn JP, Kushner RF, Cao D, Harris C, Hunter Gibble T, Stefanski A, Griffin R. Body Composition Changes During Weight Reduction with Tirzepatide in the SURMOUNT-1 Study of Adults with Obesity or Overweight. Diabetes Obes Metab. 2025. PMID: 39996356.
  3. 3.Karakasis P, Patoulias D, Fragakis N, Mantzoros CS. Effect of Glucagon-Like Peptide-1 Receptor Agonists and Co-Agonists on Body Composition: Systematic Review and Network Meta-Analysis. Metabolism. 2025. PMID: 39719170.
  4. 4.Heymsfield SB, Yang S, McCarthy C, Brown JB, Martin CK, Redman LM, Ravussin E, Shen W, Müller MJ, Bosy-Westphal A. Proportion of Caloric Restriction-Induced Weight Loss as Skeletal Muscle. Obesity (Silver Spring). 2024. PMID: 37807154.
  5. 5.Conte C, Hall KD, Klein S. Is Weight Loss-Induced Muscle Mass Loss Clinically Relevant? JAMA. 2024. PMID: 38829659.
  6. 6.Ciangura C, Bouillot JL, Lloret-Linares C, Poitou C, Veyrie N, Basdevant A, Oppert JM. Dynamics of Change in Total and Regional Body Composition After Gastric Bypass in Obese Patients. Obesity (Silver Spring). 2010. PMID: 19834464.
  7. 7.Cava E, Yeat NC, Mittendorfer B. Preserving Healthy Muscle During Weight Loss. Adv Nutr. 2017. PMID: 28507015.
  8. 8.Tinsley GM, Moore ML, Graybeal AJ, Paoli A, Kim Y, Gonzales JU, Harry JR, VanDusseldorp TA, Kennedy DN, Cruz MR. Time-Restricted Feeding Plus Resistance Training in Active Females: A Randomized Trial. Am J Clin Nutr. 2019. PMID: 31268131.
  9. 9.Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022. PMID: 35658024.
  10. 10.Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: Revised European Consensus on Definition and Diagnosis (EWGSOP2). Age Ageing. 2019. PMID: 30312372.
  11. 11.Batsis JA, Villareal DT. Sarcopenic Obesity in Older Adults: Aetiology, Epidemiology and Treatment Strategies. Nat Rev Endocrinol. 2018. PMID: 30065268.
  12. 12.Sandsdal RM, Juhl CR, Jensen SBK, Lundgren JR, Janus C, Blond MB, Rosenkilde M, Bogh AF, Gliemann L, Jensen JB, Antoniades C, Stallknecht BM, Holst JJ, Madsbad S, Torekov SS. Combination of Exercise and GLP-1 Receptor Agonist Treatment Reduces Severity of Metabolic Syndrome, Abdominal Obesity, and Inflammation: A Randomized Controlled Trial. Cardiovasc Diabetol. 2023. PMID: 36841762.
  13. 13.Phillips SM, Chevalier S, Leidy HJ. Protein 'Requirements' Beyond the RDA: Implications for Optimizing Health. Appl Physiol Nutr Metab. 2016. PMID: 26960445.
  14. 14.Devries MC, Phillips SM. Creatine Supplementation During Resistance Training in Older Adults: A Meta-Analysis. Med Sci Sports Exerc. 2014. PMID: 24576864.
  15. 15.Neeland IJ, Linge J, Birkenfeld AL. Changes in Lean Body Mass with Glucagon-Like Peptide-1-Based Therapies and Mitigation Strategies. Diabetes Obes Metab. 2024. PMID: 38937282.

Frequently Asked Questions

Yes — but it's largely a function of rapid weight loss, not a direct drug effect. In the SURMOUNT-1 (tirzepatide) DXA substudy, about 25% of weight lost was lean mass in both the drug and placebo arms, and a 2025 network meta-analysis of 22 trials put the GLP-1 class at about 25%. Other studies report shares from about 15% or less up to 40-60%. Lean-mass loss also occurs after bariatric surgery and severe calorie restriction. Strategies that mitigate it: high protein intake, resistance training, slower titration, and adequate calories.
The best-measured trial data put lean mass at about 25% of weight lost (SURMOUNT-1 DXA substudy; Karakasis 2025 meta-analysis), though some studies report more. For a patient losing 40 lb total, 25% is about 10 lb of lean mass. Lean mass includes water, organ tissue and bone as well as muscle, so muscle itself is less: a 2024 model of calorie restriction without exercise estimated about 2-2.5 kg of skeletal muscle per 10 kg lost in men and 1-1.5 kg in women. Protein and resistance training help preserve muscle during weight loss.
A 2016 review by Phillips and colleagues concluded that at least 1.2-1.6 g of high-quality protein per kg of body weight per day is a better target for adults than the 0.8 g/kg RDA. For a 200-lb (about 91 kg) patient that's about 110-145 g of protein daily, spread across meals. Some clinicians aim higher during rapid weight loss; ask your prescriber what fits you.
No. Skeletal muscle is highly responsive to resistance training at any age, and lost muscle can be regained with progressive overload + adequate protein after weight loss stabilizes. The stronger concern is the loss of muscle quality (intramuscular fat, neural drive) in older adults, which is harder to restore — making protein and resistance training during the active loss phase the better strategy.
Resistance training does not eliminate lean-mass loss during a caloric deficit, but it helps. Reviews of diet-induced weight loss find that adequate protein and exercise, particularly resistance training, help preserve muscle mass, and resistance training also improves strength. GLP-1-specific trial data on lean mass are still limited, but the underlying biology is the same: muscle protein synthesis responds to load and substrate regardless of why you're in a deficit.

Where to get semaglutide (Ozempic / Wegovy) safely: vetted online providers

Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.

No insurance needed · vetted by our editors

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money

8.2

Gala

Compounded semaglutide or tirzepatide at one all-doses price on a yearly plan, with free shipping

Read full review →

From $129/mo (starting dose)

Get started →
8.3

Found

Medication-included compounded GLP-1 from $169/mo on a 12-month prepaid plan, plus brand insurance help

Read full review →

From $169/mo (12-month plan rate)

Get started →
8.1

Oak

Compounded semaglutide and tirzepatide at a low starting price, with a full price list before you sign up

Read full review →

From $200/mo (starting dose)

Get started →